Case presentation 22-Nov-18 OT-PT 02 Mar 2007.

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

Case 2: 40-year-old Woman with Long-standing HIV Infection
Treatment in Cardiac disease The PNs Roll Dr. Sergio Diez Alvarez Staff Specialist Physician Armidale Hospital.
Acute Retroviral Syndrome
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
IAS–USA Managing Antiretroviral Failure in 2012 Jennifer Hoy, MD Professor of Medicine Director, HIV Medicine The Alfred Hospital FINAL: Presented.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Edited by Morris Sherman MD BCh PhD FRCP(C) Associate Professor of Medicine University of Toronto Protease Inhibitors in Chronic Hepatitis C: An Update.
Ischemic cardiopathy. Ischemic cardiopathy is a term used to describe patients whose heart can no longer pump enough blood to the rest of their body due.
Treatment challenges of 2 nd /3 rd line HIV/AIDS, hepatitis-C in Seychelles BY DR LOUINE MOREL.
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
Hepatitis web study Hepatitis web study PEG alfa-2a + RBV versus PEG alfa-2a versus INF + RBV APRICOT STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Unit 10 Treating the Dually Infected Patient: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Infectious Diseases.
Hep 202 Just when you thought you knew everything.
Coronary Artery Disease. What is coronary artery disease? A narrowing of the coronary arteries that prevents adequate blood supply to the heart muscle.
Ischemic Heart Diseases IHD
Anna Garcia’s Horrible Life
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
Overview of most common cardiovascular diseases Ahmad Osailan.
The good news is that many of the causes of heart disease are preventable.
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU August 27, 2014.
Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Adverse Reactions & Antiretroviral Therapy Kirsten B. Balano, PharmD October 26, 2002.
1 Hepatic Toxicity in Patients Taking ARVs HAIVN Harvard Medical School AIDS Initiative in Vietnam.
What is it? Inadequate # of RBC Sx? Pallor (paleness) dyspnea, fatigue, rapid HR Tx? Green leafy vegetables, medication, blood transfusion or bone marrow.
HIV and AIDS Global: 40M HIV positive 25M AIDS deaths from ‘80 (60% sub-Saharan Africa) 80+% male Canada:63K HIV positive 16K AIDS deaths since 1980 (83%
CASE 1 55 yo man…Baker HIV+ since 1996 Refused bloodwork over the years as was ‘Feeling fine’ Oral hairy leukoplakia noted on oral biopsy in 2001.
HIV Medications – Where We’ve Been and Where We Are Headed
Wyoming Department of Health Communicable Diseases
Enzyme Case Studies: 1 A 67 year old male two days after sustaining multiple injuries in a motor vehicle accident complains of chest pain. There is no.
VIRTUAL MEDZONE Your Resource for HIV Related Innovative Medical Communication.
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
第 22 回日本エイズ学会教育セッション Improving the Management of HIV Diseases Interactive Session Nov. 27, 2008 The 22 nd Annual Meeting of the JSAR Evening.
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Guidelines for the use of antiretroviral agents in HIV infections in Taiwan, revised in 2002 by Infectious Diseases Society of the ROC and Taiwan AIDS.
HIV INFECTION D - preventive Medicine. HIV INFECTION LEARNING OBJECTIVES  Describe the pathophysiology of HIV infection.  Describe the principal mechanisms.
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
IAS–USA Special Considerations: When and What to Start with Viral Hepatitis Coinfections Joseph J. Eron, Jr, MD Professor of Medicine University of North.
Current Concepts in HIV/AIDS A Pharmacy Perspective Carol Schneiderman, Pharm D Clinical Pharmacist, University of Arizona.
Cirrhosis Dr. Meg-angela Christi M. Amores. Cirrhosis a histopathologically defined condition – pathologic features consist of the development of fibrosis.
+ Understanding HIV-Related Lab Tests Jordan E. Lake, MD, MSc AAHU Sept 1, 2015.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
Dr. Aya M. Serry Renal Failure Renal failure is defined as a significant loss of renal function in both kidneys to the point where less than 10.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Cardiovascular Disorders Unit 7.8 Circulatory System.
Hepatitis C Infection By: S/N Maryam Omar. Introduction  Thalassemia patient require life long blood transfusion to sustain their growth and development.
Diabetes & Diabetic Foot Care Maria M. Buitrago, DPM, MS, FACFAS, FAENS.
Phase 3 Treatment-Naïve and Treatment-Experienced
TREATMENT OF HIV.
ARV-trial.com Switch to RPV/FTC/TAF Studies 1216 and
Cardiovascular Disease Coronary Heart Disease
Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2
ARV-trial.com Switch to E/C/F/TAF GS-US Study 1.
History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Just when you thought you knew everything.
Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection
Presented by: Jeanette Shabazz, PhD, NP-C
CLINICAL SOLVING PROBLEM
Switch to ATV- or ATV/r-containing regimen
Phase 3 Treatment-Naïve and Treatment-Experienced
INTRODUCTION OBJECTIVES METHODS RESULTS DISCUSSION
Presentation transcript:

Case presentation 22-Nov-18 OT-PT 02 Mar 2007

36 year old single man, living alone, successful graphic artist 10 year history of injection drug use mostly cocaine (no use since 2006) hepatitis C infection, 1999; hepatitis B immune (post-infection) injection site abscess & ulcer, 2001 humerus fractured, 2002 Bisexual with multiple partners, unprotected intercourse HIV infection discovered, 2001 HAART began (November, 2005) when CD4 = 146 cells/mm3 viral load = 329,000 copies/mL Varicella zoster, 2005 C5-6-7-8 post herpetic neuralgia poor pain control (now on amitryptiline + methadone) 22-Nov-18 OT-PT 02 Mar 2007

Examples of injection site abscesses and ulcers 22-Nov-18 OT-PT 02 Mar 2007

Humerus fracture 22-Nov-18 OT-PT 02 Mar 2007

Varicella zoster infection, right arm 22-Nov-18 OT-PT 02 Mar 2007

HAART safety AZT, 3TC, lopinavir, ritonavir (Combivir & Kaletra) Lots of nausea and mild anemia, so switched, after 3 months, to abacavir + 3TC abacavir hypersensitivity reaction, switched to ddI pancreatitis after 5 months on ddI, switched to d4T d4T peripheral neuropathy (stocking-glove, both feet) d4T stopped; switched to tenofovir (October, 2006) cholesterol increased (9.3 mmol/L), facial lipoatrophy, osteopenia HAART changed to tenofovir, 3TC, efavirenz severe dizziness and feeling “stoned”; nocturnal fall fractures wrist switched from efavirenz to atazanavir boosted with ritonavir ATZ scleral icterus (bilirubin elevated at 94 mmol/L) now, wants a drug holiday…. 22-Nov-18 OT-PT 02 Mar 2007

22-Nov-18 OT-PT 02 Mar 2007

Stocking-glove type sensory neuropathy 22-Nov-18 OT-PT 02 Mar 2007

JL Lohan before she fractured her wrist in two places in Sept 2006 22-Nov-18 OT-PT 02 Mar 2007

Colles fracture (#2) 22-Nov-18 OT-PT 02 Mar 2007

Scleral icterus 22-Nov-18 OT-PT 02 Mar 2007

HAART efficacy HIV replication CD4 restoration Viral load dropped from 329,000 c/mL before treatment to <50 c/mL after 3 months of treatment viral load has remained undetectable ever since CD4 restoration CD4 cells have not changed substantially since starting HAART /mm now about 170 cells/mm3 remains on cotrimoxazole, as prophylaxis against PCP 22-Nov-18 OT-PT 02 Mar 2007

What about liver? hepatitis C infection never evaluated before HCV RNA positive; type 1A; viral load = 4.9 million c/mL inflammation mild (AST, ALT increased) synthesis reduced slightly (INR increased) catabolism OK (bilirubin; NH3) biopsy: inflammation with early fibrosis needs treatment = pegylated interferon & ribavirin develops severe depression suicide attempt (no big “sequellae”) messes up meds (stops HAART, cotrimoxazole; pegetron & ribavirin) viral load jumps to 251,000 c/mL, one month later CD4 drop to 133 cells/mm3 hep C still present in blood hepatitis C treatment postponed until depression done HAART restarted after hiatus of two months 22-Nov-18 OT-PT 02 Mar 2007

22-Nov-18 OT-PT 02 Mar 2007

22-Nov-18 OT-PT 02 Mar 2007

Now On HAART regimen for 3 months, cough, dyspnea, 38.6ºC fever but viral load increasing (now 34,215 c/mL) CD4 cells declining (now, 109 cells/mm3) persistent fatigue; night sweats; losing weight cough, dyspnea, 38.6ºC fever interstitial pneumonitis = probable PCP never re-started cotrimoxazole broncoalveolar lavage shows Pneumocystis develops 30% pneumothorax, necessitating chest tube develops nausea and anorexia from high-dose cotrimoxazole begins dapsone but develops hypersensivity reaction PCP finally treated successfully with atovoquone chest tube removed; discharged home 22-Nov-18 OT-PT 02 Mar 2007

Normal chest x-ray on left; Pneumocystis carinii pneumonia on right Normal chest x-ray on left; Pneumocystis carinii pneumonia on right. Note the confluent interstitial pattern in the right upper lobe and the ground glass appearance obscuring the heart border 22-Nov-18 OT-PT 02 Mar 2007

HAART failure Hepatitis C infection Substance use genotyping shows HIV resistant to 3TC, ddI, abacavir, tenofovir lopinavir, ritonavir new regimen started: d4T, 3TC, TMC-114, ritonavir, TMC-125 after 2 months of new HAART regimen viral load undetectable (< 50 c/mL) CD4 increased to 178 cells/mm3 feels well; no side-effects, so far Hepatitis C infection pegetron & ribavirin to be restarted, as soon as HAART stable citalopram started to try to prevent depression Substance use pain control remains a big problem post-herpetic neuralgia HAART/HIV neuropathy old wrist fracture chest pain (chest tube, etc) 22-Nov-18 OT-PT 02 Mar 2007

New problems angina with hypercholesterolemia hip pain renal disease cardiac catheterization: 4 vessel disease; 2 stents placed on waiting list for CABG on lipid-lowering medications on medications to control blood pressure hip pain tests show early aseptic necrosis of left femoral head more pain (partial relief with NSAIDs) activities limited (cane; crutches, sometimes) on waiting list for arthroplasty renal disease multiple causes: HIV; tenofovir; NSAIDs; hypertension; substance use? 3TC dosing changed 22-Nov-18 OT-PT 02 Mar 2007

Coronary artery stent placement via cardiac catheterization 22-Nov-18 OT-PT 02 Mar 2007

Coronary artery bypass grafting Coronary artery bypass grafting. The internal mammary artery can be reditrected to perfuse the heart via a coronary artery, or segments of vessels from the leg (e.g. saphenous vein) can be used as shown here. 22-Nov-18 OT-PT 02 Mar 2007

Avascular necrosis of the femoral head, and replacement of the hip. 22-Nov-18 OT-PT 02 Mar 2007

Five health problems intersect, here: Conclusions Five health problems intersect, here: HIV infection and its diseases HCV infection and its diseases injecting drug use and its complications trauma treatment side-effects and toxicities These problems lead to a variety of transient, chronic and permanent impairments activity limitations participation restrictions 22-Nov-18 OT-PT 02 Mar 2007